Efficacy and safety of new direct oral anticoagulants in chronic kidney disease: AHA 2019 updated guidelines and review of the literature

• Glavni autori: Hubert Stępak (Autor), Zbigniew Krasiński (Autor), Andrzej Jawień (Autor), Navid Ahmadi (Autor), Adam Lipowski (Autor), Michał Stanisic (Autor)
• Format: Knjiga
• Izdano: Termedia Publishing House, 2020-01-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Direct oral anticoagulants (DOACs) are the drug of choice for the treatment of atrial fibrillation-associated systemic embolism and reducing the risk of strokes in chronic kidney disease (CKD) patients. DOACs have fewer drug-to-drug interactions as well as fewer side effects, compared to warfarin. T...